The global meningococcal vaccine market size was USD 3.54 billion in 2023, calculated at USD 3.75 billion in 2024 and is expected to reach around USD 6.36 billion by 2033, expanding at a CAGR of 6.03% from 2024 to 2033.
To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics
The U.S. meningococcal vaccine market size was exhibited at USD 1.54 billion in 2023 and is projected to be worth around USD 2.81 billion by 2033, poised to grow at a CAGR of 6.19% from 2024 to 2033.
North America dominated the global meningococcal vaccine market in 2023. The region’s growth is driven by the presence of sophisticated healthcare infrastructure, increasing prevalence of meningococcal diseases, access to effective treatment, and rise in government awareness campaigns to educate regarding the risks involved in meningitis and its required preventive measures. Moreover, supportive government policies and rising research activities focused on vaccine development are some of the prime factors expected to drive the growth of the North American market.
Among all countries, the United States is the largest meningococcal vaccine market owing to the well-developed healthcare infrastructure, rise in healthcare expenditure, presence of major pharmaceutical companies, rise in the incidence of meningitis, and favorable government initiatives for disease prevention. As a result, the demand for meningococcal vaccines has significantly increased, and timely vaccination is being carried out in the United States. Furthermore, prominent market players are investing highly in the development of an effective meningococcal vaccine in the region.
The incidence of meningococcal disease is rising in the United States. According to the CDC report in April 2024, as of March 25, 143 cases of meningococcal disease have been reported in the United States, compared with 81 for the same period in 2023. For all of 2023, 422 cases were reported, the highest annual figure since 2014.
Europe is anticipated to grow at a notable growth rate in the meningococcal vaccine market during the forecast period. The fastest growth of the region is attributed to the increasing cases of meningitis, improving access to healthcare systems, supportive government initiatives to combat the rising prevalence of the disease, and increasing new research and development activities. Additionally, rising awareness of meningococcal disease and the significance of timely vaccination are expected to contribute to the growth of the region. Partnership and collaboration among key market players in the region are expected to propel the growth of the meningococcal vaccine market.
Meningococcal disease is a rare, life-threatening, and serious disease. This disease is caused by a bacteria known as Neisseria meningitidis. It is an infection of the brain and spinal cord and can cause blood infections, too. Meningococcal vaccines play an effective role in protecting the body against infection from Neisseria meningitidis bacteria that cause meningococcal disease. By vaccination, an individual can fight against meningococcal infection. Meningococcal vaccines help to reduce the prevalence of meningitis outbreaks as well as protect and save valuable lives.
| Report Coverage | Details |
| Market Size by 2033 | USD 6.36 Billion |
| Market Size in 2023 | USD 3.54 Billion |
| Market Size in 2024 | USD 3.75 Billion |
| Market Growth Rate from 2024 to 2033 | CAGR of 6.03% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Type, End-user, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Increasing prevalence of meningitis
The increasing prevalence of meningitis across the globe is expected to boost the growth of the meningococcal vaccine market. Meningococcal disease is a serious health condition that requires immediate treatment as it affects the thin layers of tissue that cover and protect the brain and spinal cord. The proper vaccination against meningococcal infection helps prevent meningococcal disease, which is caused by Neisseria meningitidis bacterium.
Vaccines target specific serogroups of meningococcal bacteria, such as serogroups A, B, C, W, and Y, which cause meningococcal disease. Meningococcal vaccines are widely used to immunize children and infants against Neisseria meningitides bacteria. Therefore, increasing cases of meningococcal disease are expected to spur the demand for meningococcal vaccine market during the forecast period.
High cost
The high cost associated with meningococcal vaccines is projected to hamper the market's growth. It can be a financial burden for an individual to purchase this vaccine. High costs may discourage poor people from seeking vaccinations. In addition, the lack of adequate healthcare infrastructure in lower-income countries may limit the adoption and restrict the expansion of the global meningococcal vaccine market during the forecast period.
Rising awareness programs
The increasing awareness programs regarding timely vaccination to fight against meningococcal disease, coupled with supportive government and NGO incentives, are projected to create a significant growth opportunity for the meningococcal vaccine market. Several campaigns and awareness programs, such as the Meningitis Research Foundation of Canada, the National Meningitis Association (NMA), the Meningitis B Action Project, and other awareness programs. Such awareness programs assist in fueling continuous research and innovative approaches for the prevention of meningococcal disease. Thereby driving the expansion of the meningococcal vaccine market.
The conjugate vaccines segment accounted for the dominating share of the meningococcal vaccine market in 2023 owing to its high efficacy and immunization to fight against meningococcal disease. Conjugate meningococcal vaccine protects against meningococcal group A and C disease. These vaccines are recommended by healthcare professionals, particularly for infants and adolescents.
The polysaccharide vaccines segment is expected to witness considerable growth in the global meningococcal vaccine market over the forecast period. Meningococcal polysaccharide vaccine protects from bacterial meningitis. This vaccine is recommended by healthcare professionals for certain risk groups to control the meningococcal epidemic, and it is available in different forms, such as bivalent, trivalent, and tetravalent. Thereby driving the segment's growth.
The adult segment held the largest share of the meningococcal vaccine market in 2023. The growth of the segment is driven by increasing cases of meningococcal disease in adults. Adults who travel to areas with a high incidence of the disease are at higher risk of contracting the disease.
The children segment is expected to grow significantly in the meningococcal vaccine market during the forecast period owing to the rising awareness campaign by the government and NGOs about meningococcal disease coupled with increasing emphasis on vaccination as an effective and preventive measure. Routine vaccination is recommended for infants with meningococcal disease. Additionally, the ongoing clinical trials to develop novel vaccines for children are expected to fuel the segment’s expansion.
Segments Covered in the Report
By Type
By End-user
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
